Emcure Pharmaceuticals has concluded a recent United States Food and Drug Administration (US FDA) inspection at its formulations facility located in Sanand, Ahmedabad. The inspection took place between May 06, 2026, and May 15, 2026. At the end of the site review, the company received a Form 483 containing 7 procedural observations. Emcure is currently preparing a comprehensive response to address these findings within the required timeline.
Inspection Overview
Emcure Pharmaceuticals underwent a detailed inspection of its formulations manufacturing unit in Sanand, Gujarat, conducted by the United States Food and Drug Administration (US FDA). The audit, held from May 06, 2026, to May 15, 2026, focused on evaluating adherence to current Good Manufacturing Practices (cGMP).
Details of the Outcome
Following the conclusion of the inspection, the site was issued a Form 483, which highlighted 7 observations. The company has clarified that these observations are primarily procedural in nature rather than systemic quality failures. Emcure Pharmaceuticals has committed to addressing each of these points comprehensively and is currently in the process of formulating a formal response to be submitted to the US FDA within the stipulated timeframe.
Source: BSE
